In short
Forecast raised- The drug discovery support business secured 4 contracts and recorded ¥16 million in business revenue.
- Operating loss was ¥578 million due to higher R&D expenses.
- A total of 18 patients have been enrolled in the Phase 3 ACH trial of RBM-007, exceeding the required 16 patients.
What they reported
this period against the same period a year earlier, and where they now expect the year to endSales
| Period | ¥m |
|---|---|
| FY25 Q1 | 1.0 |
| FY25 Q2 | 1.0 |
| FY25 Q3 | 0.0 |
| FY25 Q4 | 0.0 |
| FY26 Q4 | 3.0 |
| FY27 Q1 | 4.0 |
| FY27 Q2 | 12.0 |
The drug discovery support business secured 3 joint research contracts and 1 outsourcing contract and recorded ¥16 million in business revenue.
創薬支援事業において、共同研究契約3件、業務委託契約1件の計4件の契約獲得を通じて、事業収益16百万円を計上。Operating profit
| Period | ¥bn |
|---|---|
| FY25 Q1 | -0.3 |
| FY25 Q2 | -0.3 |
| FY25 Q3 | -0.3 |
| FY25 Q4 | -0.3 |
| FY26 Q1 | -0.2 |
| FY26 Q2 | -0.3 |
| FY26 Q3 | -0.3 |
| FY26 Q4 | -0.4 |
| FY27 Q1 | -0.3 |
| FY27 Q2 | -0.3 |
Higher expenses, including those associated with the start of the Phase 3 clinical trial, led to a wider operating loss.
将来の事業成長に向け、ACH:第3相臨床試験開始に伴う研究開発活動を着実に推進。研究開発費は46百万円増加し、当期純損失は547百万円となりました。Ordinary profit
| Period | ¥bn |
|---|---|
| FY25 Q1 | -0.3 |
| FY25 Q2 | -0.2 |
| FY25 Q3 | -0.3 |
| FY25 Q4 | -0.3 |
| FY26 Q1 | -0.2 |
| FY26 Q2 | -0.3 |
| FY26 Q3 | -0.2 |
| FY26 Q4 | -0.4 |
| FY27 Q1 | -0.3 |
| FY27 Q2 | -0.3 |
Net profit
| Period | ¥bn |
|---|---|
| FY25 Q1 | -0.3 |
| FY25 Q2 | -0.2 |
| FY25 Q3 | -0.3 |
| FY25 Q4 | -0.3 |
| FY26 Q1 | -0.2 |
| FY26 Q2 | -0.3 |
| FY26 Q3 | -0.2 |
| FY26 Q4 | -0.4 |
| FY27 Q1 | -0.3 |
| FY27 Q2 | -0.3 |
Net loss was ¥547 million due to higher R&D expenses and other factors.
研究開発費は46百万円増加し、当期純損失は547百万円となりました。Their own numbers
figures this company chose to report, a year ago against nowThe company secured 3 joint research contracts and 1 outsourcing contract.
As of October 2026, 6 partnerships in Japan and overseas are indicated.
A total of 18 patients have been enrolled, exceeding the 16 patients required for the Phase 3 trial.
The clinical trial is being conducted at 16 institutions.
The maximum number of enrollees is stated to be 25.
The low–high ranges are Komori's estimate, not figures the company gave.
Everything else in the deck
What moved
New initiatives
- The company transitioned to a company with an Audit and Supervisory Committee and launched a new management team.
- The company added a drug discovery support business using a DDS aptamer system as a new business model.
- The company is advancing the development of novel DDS aptamer technologies, including aptamer-modified LNPs.
- The company is pursuing partnerships with companies in Japan and overseas through its DDS aptamer system.
- The company started a Phase 3 clinical trial of RBM-007 for achondroplasia.
What decks usually leave out
COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deckProgress toward the full-year forecast
¥16.0m earned of the ¥26.0m forecast. Against the old forecast (¥17.0m) it would be 94%.
The rest of the year has to bring in ¥10.0m, +9 pts off the usual pace.
| Period | % |
|---|---|
| FY23 | 5% |
| FY24 | 52% |
| FY25 | 100% |
| FY27 | 62% |
Margins and overheads
Financial targets
| Period | % |
|---|---|
| FY22 | -31.5 |
| FY23 | -36.4 |
| FY24 | -26.3 |
| FY25 | -31.6 |
| FY26 | -38.9 |
| FY27 | -54.4 |
| Period | % |
|---|---|
| FY22 | 94.7 |
| FY23 | 95.7 |
| FY24 | 95.5 |
| FY25 | 95.5 |
| FY26 | 95.4 |
| FY27 | 94.3 |
Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.
Mid-term plan targets
The deck refers to this plan, but no numeric targets were read from it.
Market size and share
The company's slice (blue) is drawn magnified so a small share stays visible; compare it with its own dashed outline from a year ago.